Ferring Pharmaceuticals (Ferring) is a private, research-driven specialty biopharmaceutical company active in global markets.
The company identifies, develops and markets innovative products in the fields of endocrinology, gastroenterology, infertility, obstetrics, urology and osteoarthritis.
In recent years Ferring has expanded beyond its traditional European base: with over 5,000 employees worldwide, it operates subsidiaries in over 60 countries and makes its products available in more than 110 countries.
The company has emerged as a world leader in research with one of the largest peptide therapeutics portfolios in the industry.
As part of its commitment to developing innovative products to treat diseases with high unmet medical need, Ferring invests heavily in its research infrastructure both in terms of people and technology.
In addition to FRI, there are two other US based Ferring affiliates headquartered in Parsippany, New Jersey.
President of the Executive Board & Chief Operating Officer, Ferring Group
Mr. Pettigrew joined Ferring in May 2001. In addition to his role as President of the Executive Board, he is responsible for all Commercial, Global Marketing, Business Development, Medical Services, Technical Operations and Research activities of the Company. He is also President and CEO of Ferring Holding US, Ferring’s largest subsidiary, and is responsible for all Clinical Development and Commercial activities in the United States. Prior to his arrival at Ferring, Mr. Pettigrew held several senior management positions throughout the world during a 21-year career with Bristol-Myers Squibb. Michel L. Pettigrew has a Bachelor of Commerce degree from McGill University in Montreal and an MBA from York University in Toronto, Canada.
Executive Vice President, Clinical and Product Development
Dr. Danglas has responsibility for all activities associated with the development of Ferring medicines and their registration globally. Dr. Danglas has a Medical Degree from the University of Paris, a CPA (Business Administration Degree) and CESAM (Statistical Degree). His vast pharmaceutical experience includes leading positions with M.S.D., Bayer and AKZO Research Center. From 1995 to 2003 Pascal Danglas was General Manager of Ferring France.
Jean Duvall Group
General Counsel & Secretary to the Board of Directors
Ms. Jean Duvall joined Ferring in November 2006. She is responsible for all legal activities on a global basis and is also the Secretary to the Board of Directors. Prior to her arrival at Ferring, Ms. Duvall was General Counsel at Elan Corporation, plc. Jean Duvall has a Bachelor of Science degree from Case Western Reserve University and a Juris Doctor degree from Ohio State University.
Executive Vice President and Chief Scientific Officer
Per Falk is responsible for overseeing all of Ferring’s Research, Development & Regulatory activities. Dr. Falk’s career includes positions as Associate Professor/Lecturer at the Dept. of Medicine at the Karolinska Institute in Stockholm and adjunct Associate Professor at the Department of Molecular Biology and Pharmacology at Washington University School of Medicine in St. Louis. In 1998, he joined AstraZeneca where he served as Head of Gastrointestinal Pharmacology and Molecular Biology. Dr. Falk joined Novo Nordisk in 2002 as VP of Experimental Medicine. From 2004, he served as VP for clinical development, medical affairs and regulatory affairs in Japan and US before returning to Denmark to serve as Senior Vice President Biopharmaceuticals Research. Dr. Falk trained and practiced medicine in Gothenburg and Stockholm and has a Ph.D. in Biochemistry from Gothenburg University.
Chief Financial Officer and Executive Vice President
Dr. Peter Wilden joined Ferring in 1991 coming from the IT & Management Consulting sector. He has occupied several leading posts within the company and became Chief Financial Officer in 2000. Dr. Wilden has a profound background in corporate taxation. He holds a degree in Business Administration and Information Technology from the University of Kiel, as well as a Ph.D. in Business Administration. Since 2004 Dr. Wilden is member of the Board of Directors and Chairman of the Audit & Compliance Committee of Lonza Group AG,Basel.
Led by President, FIPCUS and Senior Vice President, US Development-Clinical, Paul Korner, Ferring International PharmaScience Center, Inc. is charged with the identification, and clinical research and development of products within each of Ferring’s core therapeutic areas for both the US and global markets.
To learn more about Ferring International PharmaScience Center Inc., please visit www.ferringusa.com.